These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 7795572)

  • 21. Treatment of a dually diagnosed gay male patient: a psychotherapy perspective.
    Ruiz P; Lile B; Matorin AA
    Am J Psychiatry; 2002 Feb; 159(2):209-15. PubMed ID: 11823261
    [No Abstract]   [Full Text] [Related]  

  • 22. Comorbidity of psychiatric disorders and posttraumatic stress disorder.
    Brady KT; Killeen TK; Brewerton T; Lucerini S
    J Clin Psychiatry; 2000; 61 Suppl 7():22-32. PubMed ID: 10795606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Substance dependence. Information, diagnosis and therapy--encouragement for pragmatic treatment].
    Salloch-Vogel RR; Frege I
    Z Arztl Fortbild (Jena); 1996 Jun; 90(4):279-94. PubMed ID: 8928527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrating treatment innovation and research: the NIDA Experimental Therapeutics Program (Part I).
    Magura S; Rosenblum A
    J Addict Dis; 1994; 13(3):xix-xxiv. PubMed ID: 7734454
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacotherapy of comorbid mood, anxiety, and substance use disorders.
    Brady KT; Verduin ML
    Subst Use Misuse; 2005; 40(13-14):2021-41, 2043-8. PubMed ID: 16282091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [New methods for managing substance abuse by the public health office].
    Niessen J; Krause R
    Gesundheitswesen; 1995; 57(8-9):494-6. PubMed ID: 7496106
    [No Abstract]   [Full Text] [Related]  

  • 27. Anxiety disorders, comorbid substance abuse, and benzodiazepine discontinuation: implications for treatment.
    Barlow DH
    NIDA Res Monogr; 1997; 172():33-51. PubMed ID: 9154264
    [No Abstract]   [Full Text] [Related]  

  • 28. [Comparative study of substance dependence comorbidity in bipolar, schizophrenic and schizoaffective disorders].
    Verdoux H; Mury M; Besançon G; Bourgeois M
    Encephale; 1996; 22(2):95-101. PubMed ID: 8706627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic strategies for the patient with treatment-resistant anxiety.
    Coplan JD; Tiffon L; Gorman JM
    J Clin Psychiatry; 1993 May; 54 Suppl():69-74. PubMed ID: 8509358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical guidelines for the treatment of depressive disorders. VII. Comorbidity.
    Enns MW; Swenson JR; McIntyre RS; Swinson RP; Kennedy SH;
    Can J Psychiatry; 2001 Jun; 46 Suppl 1():77S-90S. PubMed ID: 11441774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathways to comorbidity: the transition of pure mood, anxiety and substance use disorders into comorbid conditions in a longitudinal population-based study.
    de Graaf R; Bijl RV; Ten Have M; Beekman AT; Vollebergh WA
    J Affect Disord; 2004 Nov; 82(3):461-7. PubMed ID: 15555699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adolescents with insomnia and substance abuse: consequences and comorbidities.
    Shibley HL; Malcolm RJ; Veatch LM
    J Psychiatr Pract; 2008 May; 14(3):146-53. PubMed ID: 18520783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of co-occurring mood and anxiety disorders among substance-abusing youth.
    Lubman DI; Allen NB; Rogers N; Cementon E; Bonomo Y
    J Affect Disord; 2007 Nov; 103(1-3):105-12. PubMed ID: 17291589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three year outcomes of an early intervention for psychosis service as compared with treatment as usual for first psychotic episodes in a standard community mental health team - final results.
    Agius M; Shah S; Ramkisson R; Murphy S; Zaman R
    Psychiatr Danub; 2007 Sep; 19(3):130-8. PubMed ID: 17914313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comorbidity in generalized anxiety disorder: impact and implications.
    Stein DJ
    J Clin Psychiatry; 2001; 62 Suppl 11():29-34; discussion 35-6. PubMed ID: 11414548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of anxiety disorder comorbidity on treatment resistant bipolar disorders.
    Lee JH; Dunner DL
    Depress Anxiety; 2008; 25(2):91-7. PubMed ID: 17311265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Magnitude and impact of comorbidity of mental disorders from epidemiologic surveys.
    Merikangas KR; Kalaydjian A
    Curr Opin Psychiatry; 2007 Jul; 20(4):353-8. PubMed ID: 17551350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Anxiety disorders and substance-related disorders].
    Ochoa Mangado E
    Actas Esp Psiquiatr; 1999; 27(1):56-63. PubMed ID: 10380148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Psychotropic drugs outside of psychiatry, especially in advanced age].
    Barolin GS
    Wien Med Wochenschr; 1993; 143(9):236-44. PubMed ID: 8351936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychiatric disorders and their comorbidity in subjects with parasuicide by intentional drug overdose: prevalence and gender differences.
    Tournier M; Molimard M; Cougnard A; Abouelfath A; Fourrier A; Verdoux H
    Psychiatry Res; 2005 Sep; 136(2-3):93-100. PubMed ID: 16112202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.